TC
STLN

T3 Companies’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

T3 Companies’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Sell
80,000
-31,900
-29% -$134K 0.46% 47
2026
Q1 		$344K Sell
111,900
-89,200
-44% -$274K 0.45% 40
2025
Q4 		$716K Buy
+201,100
New +$746K 0.89% 22

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

T3 Companies's STLN Position: Q2 2026 in Review

T3 Companies reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 29% in Q2 2026, selling an estimated $134K and leaving 80,000 shares worth $434K. The position accounts for 0.46% of the portfolio, ranked #47.

T3 Companies first reported a position in STLN in Q4 2025 and has held it in 3 quarters since. The position peaked at $716K in Q4 2025. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • T3 Companies held 80,000 shares of Starling Oncology Institute, Inc. Common Stock worth $434K as of Q2 2026.
  • T3 Companies sold 31,900 Starling Oncology Institute, Inc. Common Stock shares in Q2 2026, an estimated $134K.
  • Starling Oncology Institute, Inc. Common Stock made up 0.46% of T3 Companies's portfolio in Q2 2026, its #47 holding.
  • T3 Companies first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and has held it in 3 quarters since.
  • T3 Companies's Starling Oncology Institute, Inc. Common Stock position peaked at $716K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.